Physician profile
Paul C Gering
NPI 1235198995
$1,829.61
in general payments reported to CMS, 2019-2025
27 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $362 · 2021: $276 · 2022: $355 · 2023: $127 · 2024: $209 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $296.27 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $213.70 | 2020-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $209.10 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $203.45 | 2019-2025 | Eliquis |
| Novo Nordisk INC | $194.81 | 2019-2025 | Rybelsus, Ozempic |
| Biodelivery Sciences International, INC. | $88.36 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.72 | 2021-2023 | |
| Pfizer INC. | $66.60 | 2019-2021 | |
| Lilly USA, LLC | $57.57 | 2019-2023 | Mounjaro |
| Astellas Pharma US INC | $44.21 | 2019-2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $40.38 | 2022 | |
| Allergan, INC. | $40.29 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.50 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $31.53 | 2019-2022 | |
| Mylan Specialty L.P. | $28.01 | 2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $26.94 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $19.60 | 2021 | |
| Abbott Laboratories | $19.01 | 2022 | |
| Viatris Specialty LLC | $18.92 | 2025 | Yupelri |
| Arbor Pharmaceuticals, INC. | $16.87 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.99 | 2025 | Gvoke Hypopen |
| Philips North America LLC | $15.79 | 2020 | |
| Glaxosmithkline, LLC. | $14.34 | 2023 | Shingrix |
| Alnylam Pharmaceuticals INC. | $14.28 | 2024 | Amvuttra |
| Dexcom, INC. | $12.93 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $12.00 | 2020 | |
| Amarin Pharma, INC. | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.